# Hodgkin Lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hodgkin-lymphoma

> 2 upcoming FDA catalysts in Hodgkin Lymphoma: KEYTRUDA® (pembrolizumab, MRK) on Feb to May 2027 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on February 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 3, 2025 | [Favezelimab/pembrolizumab primary completion](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867)) |
| January 14, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT02684292 (Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02684292)) |
| September 1, 2026 | [Favezelimab/pembrolizumab topline data readout](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867?tab=results)) |
| Feb to May 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | scheduled | "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03407144)) |
| February 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | scheduled | "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03407144)) |

## Drugs

- [Favezelimab/pembrolizumab](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) (MRK)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hodgkin-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hodgkin Lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hodgkin-lymphoma

```bibtex
@misc{secapidev_indications_hodgkin_lymphoma_20261116,
  title        = {Hodgkin Lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hodgkin-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hodgkin_lymphoma_20261116","title":"Hodgkin Lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hodgkin-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
